Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 5/20 | 0.38 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.35 |
| ▸ | RXRA | P19793 | 1/20 | 0.35 |
| ▸ | RXRB | P28702 | 1/20 | 0.35 |
| ▸ | RXRG | P48443 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 4/20 | 0.34 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 2/20 | 0.32 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.32 |
| ▸ | PTGES | O14684 | 1/20 | 0.31 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.31 |
| ▸ | IDO1 | P14902 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31355231 | 0.86 | MAP4K1 (0.33) | ALDH1A1CYP1A2CYP3A4CYP2C9CYP2C19 | |
| SCHEMBL31076279 | 0.74 | FFAR4 (0.41) | FFAR1NR4A2RXRARXRBRXRG | |
| SCHEMBL27191951 | 0.73 | FFAR1 (0.37) | FFAR1NR4A2RXRARXRBRXRG | |
| SCHEMBL32677636 | 0.72 | FFAR1 (0.46) | FFAR1NR4A2RXRARXRBRXRG | |
| SCHEMBL31076243 | 0.72 | FFAR1 (0.46) | FFAR1NR4A2RXRARXRBRXRG | |
| SCHEMBL27192180 | 0.69 | NPC1 (0.36) | FFAR1NR4A2RXRARXRBRXRG | |
| SCHEMBL23543046 | 0.68 | FFAR1 (0.42) | FFAR1CYP2C9 | |
| SCHEMBL22886084 | 0.68 | KDM4E (0.38) | FFAR1FFAR4ALDH1A1 | |
| SCHEMBL31076304 | 0.67 | GPR88 (0.40) | FFAR1NR4A2RXRARXRBRXRG | |
| SCHEMBL332441 | 0.66 | CYP4F2 (0.31) | FFAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250376482-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2025-12-11 | — | — | US | disclosed |
| US-12247036-B2 | Tricyclic compounds for the treatment of cancer | HOFFMANN-LA ROCHE INC. (US) | 2025-03-11 | — | — | US | disclosed |
| US-20240417410-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | HOFFMANN-LA ROCHE INC. (US) | 2024-12-19 | — | — | US | disclosed |
| EP-4469164-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | F. Hoffmann-La Roche AG (CH) | 2024-12-04 | — | — | EP | disclosed |
| WO-2024169914-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2024-08-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250376482-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B | FFAR1 2784/4885NR4A2 1332/4885RXRA 2322/4885 |
| US-20240417410-A1 | TRICYCLIC COMPOUNDS FOR THE TREATMENT OF CANCER | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B | FFAR1 2784/4885NR4A2 1332/4885RXRA 2322/4885 |
| US-12247036-B2 | Tricyclic compounds for the treatment of cancer | H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CCNI, TOP2B | FFAR1 2784/4885NR4A2 1332/4885RXRA 2322/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.